 |
96 Diseases |  |
29 Trials |
|
29 Trials |  |
1185 News |  |
| «12...45678910111213141516» |
- | lomustine / Generic mfg., temozolomide / Generic mfg., vincristine / Generic mfg.
Clinical, Journal: Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. (Pubmed Central) - Feb 8, 2019
Older age (OR 1.08, p = 0.02) and duration of adjuvant chemotherapy (OR 1.19, p = 0.003) were significantly associated with grade ≥ 1 lymphopenia at 12 months. Thus, concurrent chemotherapy appears as the dominant contributor to the severity of acute lymphopenia after RT in WHO grade II-III glioma patients, and duration of adjuvant chemotherapy appears as the key factor to prolonged lymphopenia.
- ||| Inlyta (axitinib) / Pfizer
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: AxiGII: A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Jan 24, 2019
P2, N=56, Completed, Sponsor: Bart Neyns
Thus, concurrent chemotherapy appears as the dominant contributor to the severity of acute lymphopenia after RT in WHO grade II-III glioma patients, and duration of adjuvant chemotherapy appears as the key factor to prolonged lymphopenia. Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Aug 2018
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker: A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer (clinicaltrials.gov) - Jan 24, 2019
P1, N=90, Recruiting, Sponsor: John Wayne Cancer Institute
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Aug 2018 N=45 --> 90 | Trial completion date: Feb 2020 --> Feb 2022 | Trial primary completion date: Feb 2019 --> Feb 2021
- | lomustine / Generic mfg., cisplatin / Generic mfg., vincristine / Generic mfg.
Clinical, Journal: Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). (Pubmed Central) - Jan 19, 2019
Thus, we propose frequent patient surveillance using this regimen. Modifications of the regimen may increase feasibility of radio-polychemotherapy of adult patients with medulloblastoma.
- | Trial suspension, Surgery: Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma (clinicaltrials.gov) - Jan 17, 2019
P=N/A, N=13, Suspended, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Modifications of the regimen may increase feasibility of radio-polychemotherapy of adult patients with medulloblastoma. Recruiting --> Suspended
- ||| USL311 / Sawai Pharma
Enrollment open, Trial primary completion date, Combination therapy, Metastases: Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Jan 17, 2019
P1/2, N=120, Recruiting, Sponsor: Proximagen, LLC
Recruiting --> Suspended Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Sep 2022
- | lomustine / Generic mfg., temozolomide / Generic mfg., vincristine / Generic mfg.
Review, Journal: Chemotherapy Treatment and Trials in Low-Grade Gliomas. (Pubmed Central) - Jan 12, 2019
The addition of combination chemotherapy with procarbazine, lomustine, and vincristine confers survival advantage, as likely does temozolomide, but radiochemotherapy may not be appropriate for all patients owing to its toxicity profile. We review the approach to treatment in patients with low-grade gliomas with an emphasis on the clinical trials focusing on adjuvant chemotherapy in this population.
- | Avastin (bevacizumab) / Roche
Journal: Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. (Pubmed Central) - Dec 29, 2018
These findings suggest that when adjuvant treatment is clinically indicated for PXA, temozolomide, CPT 11, or bevacizumab may be considered. Additionally, a trial of a MEK inhibitor or tyrosine kinase inhibitor could be considered for PXA regardless of V600E mutation status.
- | lomustine / Generic mfg.
Journal: The lomustine crisis: awareness and impact of the 1500% price hike. (Pubmed Central) - Dec 28, 2018
Additionally, a trial of a MEK inhibitor or tyrosine kinase inhibitor could be considered for PXA regardless of V600E mutation status. No abstract available
- |||| elraglusib (9-ING-41) / Actuate Therap
Enrollment open, Metastases: Actuate 1801: 9-ING-41 in Patients with Advanced Cancers (clinicaltrials.gov) - Dec 11, 2018
P1/2, N=250, Recruiting, Sponsor: Actuate Therapeutics Inc.
No abstract available Not yet recruiting --> Recruiting
- ||| Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment closed, Enrollment change: Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 4, 2018
P2, N=7, Active, not recruiting, Sponsor: AIDS Malignancy Consortium
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=90 --> 7
- | chlorogenic acid / Jiuzhang Biotech
New P2/3 trial: Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients (clinicaltrials.gov) - Nov 29, 2018
P2/3, N=200, Recruiting, Sponsor: Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
- | galunisertib (LY2157299) / Eli Lilly
Trial completion date, Combination therapy, Monotherapy: A Dose-Escalation Study in Participants With Recurrent Malignant Glioma (clinicaltrials.gov) - Nov 23, 2018
P1, N=66, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=90 --> 7 Trial completion date: Oct 2018 --> May 2019
- | galunisertib (LY2157299) / Eli Lilly
Trial completion date, Monotherapy: A Study in Recurrent Glioblastoma (GB) (clinicaltrials.gov) - Nov 21, 2018
P2, N=180, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Oct 2018 --> May 2019 Trial completion date: Dec 2018 --> Dec 2019
- | vocimagene amiretrorepvec/extended release flucytosine (DB107) / Denovo
Enrollment closed: Toca5: The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - Nov 15, 2018
P2/3, N=380, Active, not recruiting, Sponsor: Tocagen Inc.
Trial completion date: Dec 2018 --> Dec 2019 Recruiting --> Active, not recruiting
- || depatuxizumab mafodotin (ABT-414) / AbbVie
Trial completion date: RTOG Foundation 3508: Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (clinicaltrials.gov) - Nov 5, 2018
P2, N=260, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Trial completion date: Jun 2020 --> Dec 2020
- | Trial completion date, Trial primary completion date, Surgery: Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma (clinicaltrials.gov) - Oct 22, 2018
P=N/A, N=13, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Jun 2020 --> Dec 2020 Trial completion date: Aug 2019 --> May 2022 | Trial primary completion date: Aug 2018 --> May 2021
- | elraglusib (9-ING-41) / Actuate Therap
New P1/2 trial, Metastases: Actuate 1801: 9-ING-41 in Patients with Advanced Cancers (clinicaltrials.gov) - Sep 19, 2018
P1/2, N=250, Not yet recruiting, Sponsor: Actuate Therapeutics Inc.
- | Sutent (sunitinib) / Pfizer
Enrollment open, Trial initiation date: STELLAR: A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Sep 5, 2018
P2/3, N=100, Recruiting, Sponsor: VU University Medical Center
Trial completion date: Aug 2019 --> May 2022 | Trial primary completion date: Aug 2018 --> May 2021 Not yet recruiting --> Recruiting | Initiation date: Aug 2017 --> Aug 2018
- | Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
Enrollment open: Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Aug 31, 2018
P2, N=56, Recruiting, Sponsor: Aadi, LLC
Not yet recruiting --> Recruiting | Initiation date: Aug 2017 --> Aug 2018 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Journal, IO biomarker: High-grade Gliomas. (Pubmed Central) - Aug 10, 2018
Despite aggressive treatment, these tumors progress, and overall outcomes have not changed much in the past decade. However, our understanding of the disease is improving, and newer therapies appear promising.
- | lomustine / Generic mfg., temozolomide / Generic mfg., vincristine / Generic mfg.
Journal: Low-grade Gliomas. (Pubmed Central) - Aug 10, 2018
While the combination of radiation and PCV provides the best proven overall survival with low-grade gliomas, important questions remain. These include whether the better-tolerated temozolomide is as effective as PCV in conjunction with radiation therapy and whether the use of initial chemotherapy as a strategy to defer the potential delayed cognitive toxicity associated with radiation will yield acceptable survival results with a favorable toxicity profile.
- | NN1213 / Novo Nordisk
Enrollment open, Trial initiation date: LEAHRN: Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma (clinicaltrials.gov) - Aug 7, 2018
P2, N=45, Recruiting, Sponsor: Children's Oncology Group
These include whether the better-tolerated temozolomide is as effective as PCV in conjunction with radiation therapy and whether the use of initial chemotherapy as a strategy to defer the potential delayed cognitive toxicity associated with radiation will yield acceptable survival results with a favorable toxicity profile. Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> Oct 2017
- | buparlisib (AN2025) / Adlai Nortye
Phase classification: Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Aug 3, 2018
P1, N=35, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> Oct 2017 Phase classification: P1/2 --> P1
- | Biomarker, Clinical, P2 data, Journal, Monotherapy: Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials. (Pubmed Central) - Jul 20, 2018
P2
These findings were validated using a separate trial comparing bevacizumab with lomustine.Experimental Design: Patients with recurrent GBM and diffusion MRI from the monotherapy arms of 5 separate phase II clinical trials were included: (i) cediranib (NCT00035656); (ii) bevacizumab (BRAIN Trial, AVF3708g; NCT00345163); (iii) cabozantinib (XL184-201; NCT00704288); (iv) aflibercept (VEGF Trap; NCT00369590); and (v) bevacizumab or lomustine (BELOB; NTR1929)...An ADCL threshold of 1.24 um(2)/ms produced the largest OS differences between patients (HR~0.5) and patients with an ADCL>1.24 um(2)/ms had close to double the OS in all anti-VEGF therapeutic scenarios tested. Training and validation data confirmed baseline ADCL was an independent predictive biomarker for OS in anti-VEGF therapies, but not lomustine, after accounting for age and baseline enhancing tumor volume. Pre-treatment diffusion MRI is a predictive imaging biomarker for OS in patients with recurrent GBM treated with anti-VEGF monotherapy at first or second relapse.
- ||| Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment open: Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 21, 2018
P2, N=90, Recruiting, Sponsor: AIDS Malignancy Consortium
Training and validation data confirmed baseline ADCL was an independent predictive biomarker for OS in anti-VEGF therapies, but not lomustine, after accounting for age and baseline enhancing tumor volume. Pre-treatment diffusion MRI is a predictive imaging biomarker for OS in patients with recurrent GBM treated with anti-VEGF monotherapy at first or second relapse. Suspended --> Recruiting
- | Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion, Trial completion date: SWOG-R9802: Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma (clinicaltrials.gov) - Jun 2, 2018
P2/3, N=370, Completed, Sponsor: Radiation Therapy Oncology Group
Suspended --> Recruiting Active, not recruiting --> Completed | Trial completion date: Aug 2020 --> May 2018
- ||||| Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
New P2 trial: Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Mar 12, 2018
P2, N=56, Not yet recruiting, Sponsor: Aadi, LLC
- ||| Avastin (bevacizumab) / Roche
Trial completion date: EORTC 26101: Bevacizumab and Lomustine for Recurrent GBM (clinicaltrials.gov) - Mar 3, 2018
P3, N=433, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed | Trial completion date: Aug 2020 --> May 2018 Trial completion date: Oct 2017 --> Aug 2018
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Surgery: Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma (clinicaltrials.gov) - Feb 26, 2018
P=N/A, N=6, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Oct 2017 --> Aug 2018 Trial primary completion date: Feb 2018 --> Feb 2019 | Trial completion date: Feb 2018 --> Feb 2019
- ||||| dianhydrogalactitol (VAL-083) / Valent Tech
Enrollment closed: STAR-3: VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM (clinicaltrials.gov) - Feb 22, 2018
P3, N=180, Active, not recruiting, Sponsor: DelMar Pharmaceuticals, Inc.
Trial primary completion date: Feb 2018 --> Feb 2019 | Trial completion date: Feb 2018 --> Feb 2019 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial, PD(L)-1 Biomarker: A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer (clinicaltrials.gov) - Feb 7, 2018
P1, N=45, Not yet recruiting, Sponsor: John Wayne Cancer Institute
- | erteberel (LY500307) / Eli Lilly
Journal: Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. (Pubmed Central) - Jan 24, 2018
LY500307 treatment significantly reduced the in vivo tumor growth and promoted apoptosis of GBM tumors in an orthotopic model and improved the overall survival of tumor-bearing mice in the GL26 syngeneic glioma model. Our results demonstrate that LY500307 has potential as a therapeutic agent for GBM.
- | VBI-1901 / VBI Vaccines
New P1/2 trial: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects (clinicaltrials.gov) - Dec 26, 2017
P1/2, N=18, Recruiting, Sponsor: VBI Vaccines Inc.
- | Avastin (bevacizumab) / Roche
Clinical, P2 data, Journal: A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. (Pubmed Central) - Dec 25, 2017
Although the study was not designed to exclusively evaluate patients at first recurrence, a strong trend towards improved PFS was seen in that subgroup for the combination of low dose bevacizumab plus lomustine. Further studies are needed to better identify such subgroups that may most benefit from the combination treatment.
- | Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial suspension: Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 21, 2017
P2, N=90, Suspended, Sponsor: AIDS Malignancy Consortium
Further studies are needed to better identify such subgroups that may most benefit from the combination treatment. Recruiting --> Suspended
- |||||| vocimagene amiretrorepvec/extended release flucytosine (DB107) / Denovo
Enrollment open: Toca5: The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - Nov 17, 2017
P2/3, N=380, Recruiting, Sponsor: Tocagen Inc.
Recruiting --> Suspended Active, not recruiting --> Recruiting
- | lomustine / Generic mfg.
Enrollment open: Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma (clinicaltrials.gov) - Nov 9, 2017
P2, N=34, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| vocimagene amiretrorepvec/extended release flucytosine (DB107) / Denovo
Enrollment change, Trial primary completion date: Toca5: The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - Oct 30, 2017
P2/3, N=380, Active, not recruiting, Sponsor: Tocagen Inc.
Not yet recruiting --> Recruiting N=187 --> 380 | Trial primary completion date: Nov 2017 --> Dec 2019
- | Stivarga (regorafenib) / Bayer
Enrollment closed, Trial primary completion date: REGOMA: Regorafenib in Relapsed Glioblastoma (clinicaltrials.gov) - Oct 9, 2017
P2, N=119, Active, not recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
N=187 --> 380 | Trial primary completion date: Nov 2017 --> Dec 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Jul 2017
- | USL311 / Sawai Pharma
Enrollment closed, Combination therapy, Metastases: Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Sep 12, 2017
P1/2, N=120, Active, not recruiting, Sponsor: Proximagen, LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Jul 2017 Recruiting --> Active, not recruiting
- | lomustine / Generic mfg.
Trial initiation date, Trial primary completion date: Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma (clinicaltrials.gov) - Sep 6, 2017
P2, N=37, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Initiation date: Aug 2017 --> Dec 2017 | Trial primary completion date: Aug 2021 --> Dec 2021
- | Avastin (bevacizumab) / Roche
Enrollment open, Metastases: Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI (clinicaltrials.gov) - Aug 31, 2017
P=N/A, N=85, Recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Aug 2017 --> Dec 2017 | Trial primary completion date: Aug 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- | lomustine / Generic mfg., temozolomide / Generic mfg.
Journal: Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. (Pubmed Central) - Aug 23, 2017
Not yet recruiting --> Recruiting The addition of lomustine to temozolomide as adjuvant therapy in ACNS0423 was associated with significantly improved outcome compared with the preceding COG ACNS0126 HGG study in which participants received temozolomide alone.
- | Journal: Hypothalamic-Pituitary Axis Dysfunction in Survivors of Childhood CNS Tumors: Importance of Systematic Follow-Up and Early Endocrine Consultation. (Pubmed Central) - Aug 9, 2017
The patient was referred to the endocrinology clinic where he was diagnosed with growth hormone deficiency and was started on replacement therapy. He reached his final adult height of 144.1 cm at age 13.3 years ( Fig 1 , point d).
- |||||| dianhydrogalactitol (VAL-083) / Valent Tech
Enrollment open: STAR-3: VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM (clinicaltrials.gov) - Jul 31, 2017
P3, N=180, Recruiting, Sponsor: DelMar Pharmaceuticals, Inc.
He reached his final adult height of 144.1 cm at age 13.3 years ( Fig 1 , point d). Active, not recruiting --> Recruiting
- |||| Avastin (bevacizumab) / Roche
Trial completion, Phase classification: A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma (clinicaltrials.gov) - Jul 28, 2017
P2, N=299, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Phase classification: P3 --> P2
- ||||| dianhydrogalactitol (VAL-083) / Valent Tech
Enrollment closed: STAR-3: VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM (clinicaltrials.gov) - Jul 28, 2017
P3, N=180, Active, not recruiting, Sponsor: DelMar Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Phase classification: P3 --> P2 Not yet recruiting --> Active, not recruiting
- | lomustine / Generic mfg.
Trial initiation date, Trial primary completion date: Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma (clinicaltrials.gov) - Jun 19, 2017
P2, N=37, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Active, not recruiting Initiation date: May 2017 --> Aug 2017 | Trial primary completion date: May 2021 --> Aug 2021
- | lomustine / Generic mfg., ifosfamide / Generic mfg., cisplatin / Generic mfg.
Journal: Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. (Pubmed Central) - Jun 15, 2017
However, our findings should provide reassurance to most female survivors treated with chemotherapy without radiotherapy to the pelvis or brain, given that chemotherapy-specific effects on pregnancy were generally few. Nevertheless, consideration of fertility preservation before cancer treatment remains important to maximise the reproductive potential of all adolescents newly diagnosed with cancer.